S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NYSEAMERICAN:IBIO

iBio Stock Competitors

$0.71
+0.05 (+7.56%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.67
$0.73
50-Day Range
N/A
52-Week Range
$0.56
$2.83
Volume
2.09 million shs
Average Volume
8.43 million shs
Market Capitalization
$154.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-5.96

iBio (NYSEAMERICAN:IBIO) Vs. EGRX, VERA, OGI, PHAT, IMGO, ORIC, AMTI, DMCAF, THRX, and PNT

Should you be buying iBio stock or one of its competitors? The main competitors of iBio include Eagle Pharmaceuticals (EGRX), Vera Therapeutics (VERA), OrganiGram (OGI), Phathom Pharmaceuticals (PHAT), Imago BioSciences (IMGO), ORIC Pharmaceuticals (ORIC), Applied Molecular Transport (AMTI), DiaMedica Therapeutics (DMCAF), Theseus Pharmaceuticals (THRX), and POINT Biopharma Global (PNT). These companies are all part of the "pharmaceutical preparations" industry.

iBio vs.

iBio (NYSEAMERICAN:IBIO) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.

19.9% of iBio shares are owned by institutional investors. Comparatively, 64.7% of Vera Therapeutics shares are owned by institutional investors. 0.8% of iBio shares are owned by company insiders. Comparatively, 9.3% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vera Therapeutics has a net margin of 0.00% compared to iBio's net margin of -1,133.19%. Vera Therapeutics' return on equity of 0.00% beat iBio's return on equity.

Company Net Margins Return on Equity Return on Assets
iBio -1,133.19% -33.06% -24.06%
Vera Therapeutics N/A N/A -79.45%

iBio has higher revenue and earnings than Vera Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iBio$2.37 million65.39-$23.21 million-$0.12-5.93
Vera TherapeuticsN/AN/A-$53.41 millionN/AN/A

iBio presently has a consensus target price of $2.25, suggesting a potential upside of 216.46%. Vera Therapeutics has a consensus target price of $24.00, suggesting a potential downside of 16.93%. Given iBio's higher possible upside, equities research analysts plainly believe iBio is more favorable than Vera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iBio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Vera Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Vera Therapeutics had 5 more articles in the media than iBio. MarketBeat recorded 5 mentions for Vera Therapeutics and 0 mentions for iBio. Vera Therapeutics' average media sentiment score of 0.55 beat iBio's score of 0.48 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
iBio Neutral
Vera Therapeutics Positive

iBio received 164 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 76.82% of users gave iBio an outperform vote while only 55.56% of users gave Vera Therapeutics an outperform vote.

CompanyUnderperformOutperform
iBioOutperform Votes
169
76.82%
Underperform Votes
51
23.18%
Vera TherapeuticsOutperform Votes
5
55.56%
Underperform Votes
4
44.44%

Summary

Vera Therapeutics beats iBio on 7 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSEAMERICAN and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

iBio (NYSEAMERICAN:IBIO) vs. Its Competitors

TypeiBioPharmaceutical IndustryMedical SectorNYSEAMERICAN Exchange
Market Cap$154.97M$5.81B$4.96B$656.56M
Dividend YieldN/A2.63%2.05%2.96%
P/E Ratio-5.9316.2722.318.71
Price / Sales65.39554.222,429.35169.45
Price / CashN/A146.2661.8814.15
Price / Book1.555.666.153.23
Net Income-$23.21M$95.55M$96.04M-$15.02M
7 Day PerformanceN/A1.10%0.98%1.42%
1 Month PerformanceN/A-14.00%-12.06%-22.91%
1 Year Performance-45.73%5.47%9.29%32.47%

iBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EGRX
Eagle Pharmaceuticals
2.2514 of 5 stars
$47.62
+2.1%
$51.00
+7.1%
+1.8%$614.97M$187.80M116.15106
VERA
Vera Therapeutics
1.3798 of 5 stars
$28.89
+5.8%
$24.00
+16.9%
N/A$605.77MN/A0.0019
OGI
OrganiGram
1.7098 of 5 stars
$2.00
+6.5%
$4.04
+101.8%
+37.0%$599.69M$62.43M-4.65517
PHAT
Phathom Pharmaceuticals
2.3665 of 5 stars
$19.06
+1.7%
$60.25
+216.1%
-60.7%$598.77MN/A-4.2255
IMGO
Imago BioSciences
1.7048 of 5 stars
$17.80
+8.9%
$32.00
+79.8%
N/A$596.82MN/A0.002,021Gap Up
High Trading Volume
ORIC
ORIC Pharmaceuticals
2.4664 of 5 stars
$15.10
+4.0%
$26.33
+74.4%
-58.4%$594.67MN/A-6.4861
AMTI
Applied Molecular Transport
2.825 of 5 stars
$15.40
+6.3%
$80.33
+421.6%
-49.9%$592.75MN/A-6.8180
DMCAF
DiaMedica Therapeutics
0.7998 of 5 stars
$3.77
+4.2%
N/A-33.7%$592.42MN/A0.00N/A
THRX
Theseus Pharmaceuticals
2.0095 of 5 stars
$15.19
+0.7%
$25.00
+64.6%
N/A$587.90MN/A0.00N/A
PNT
POINT Biopharma Global
1.4531 of 5 stars
$6.50
+4.3%
$17.75
+173.1%
N/A$585.79MN/A0.00N/AGap Up
High Trading Volume
SIGA
SIGA Technologies
0.7066 of 5 stars
$7.90
+7.2%
N/A+13.5%$585.52M$124.96M39.5042High Trading Volume
ENOB
Enochian Biosciences
0.3333 of 5 stars
$11.03
+7.3%
N/A+279.0%$575.99MN/A0.0010Gap Up
IVA
Inventiva
1.4798 of 5 stars
$13.65
+0.3%
$42.00
+207.7%
+16.0%$556.14M$430K0.0088
EPIX
ESSA Pharma
2.0333 of 5 stars
$12.59
+5.0%
$34.67
+175.4%
+82.7%$553.76MN/A-12.9825Gap Up
KPTI
Karyopharm Therapeutics
2.4067 of 5 stars
$7.26
+7.4%
$14.83
+104.3%
-53.3%$548.47M$108.08M-2.63432
CMRX
Chimerix
2.0381 of 5 stars
$6.24
+3.0%
$18.00
+188.5%
+37.4%$542.02M$5.37M-3.4354
PHAR
Pharming Group
1.0415 of 5 stars
$8.30
+4.7%
N/AN/A$536.54M$212.10M0.00262Analyst Upgrade
Gap Up
ABUS
Arbutus Biopharma
2.0981 of 5 stars
$3.96
+6.3%
$6.90
+74.2%
+0.3%$535.67M$6.91M-4.3577News Coverage
Gap Up
High Trading Volume
ANIP
ANI Pharmaceuticals
2.7881 of 5 stars
$41.87
+4.1%
$68.33
+63.2%
+41.2%$533.93M$208.48M-22.88369Positive News
IMRX
Immuneering
1.6265 of 5 stars
$20.58
+1.9%
$43.67
+112.2%
N/A$533.87MN/A0.002,021Gap Up
PYR
PyroGenesis Canada
0 of 5 stars
$3.01
+2.3%
N/AN/A$514.10M$13.27M60.212,020
SMMT
Summit Therapeutics
1.1331 of 5 stars
$5.24
+4.0%
N/A+5.0%$512.02M$20.17M-6.0980Analyst Report
NKTX
Nkarta
2.3531 of 5 stars
$15.48
+10.7%
$70.80
+357.4%
-68.0%$510.05M$120K-6.2495Gap Up
VERU
Veru
1.9931 of 5 stars
$6.35
+2.7%
$19.40
+205.5%
+89.6%$507.07M$61.26M57.73339Earnings Report
Analyst Revision
Gap Up
OCUL
Ocular Therapeutix
2.0398 of 5 stars
$6.61
+6.5%
$24.00
+263.1%
-66.8%$506.39M$17.40M-3.42181Analyst Report
BPMUF
Basilea Pharmaceutica
0.9248 of 5 stars
$47.00
+0.0%
N/AN/A$504.78M$136.11M0.00157
ICPT
Intercept Pharmaceuticals
2.4093 of 5 stars
$16.95
+4.5%
$29.67
+75.0%
-50.0%$500.82M$312.69M-5.23498Gap Up
PLRX
Pliant Therapeutics
2.0333 of 5 stars
$13.80
+6.1%
$47.40
+243.5%
-49.2%$497.34M$41.82M-5.3778Gap Up
High Trading Volume
RYTM
Rhythm Pharmaceuticals
1.8564 of 5 stars
$9.83
+5.8%
$36.33
+269.6%
-65.6%$494.13MN/A-7.6290
GTHX
G1 Therapeutics
1.8531 of 5 stars
$11.42
+4.8%
$45.67
+299.9%
-36.1%$485.60M$45.28M-3.50122Gap Up
PHVS
Pharvaris
1.9331 of 5 stars
$15.25
+2.5%
$47.50
+211.5%
N/A$485.56MN/A0.0014Gap Down
DCPH
Deciphera Pharmaceuticals
2.3298 of 5 stars
$8.30
+3.3%
$29.10
+250.6%
-85.1%$485.39M$42.09M-1.75350
AVDL
Avadel Pharmaceuticals
1.8714 of 5 stars
$8.28
+1.0%
$16.50
+99.3%
+21.9%$485.37M$22.33M-7.332,020
OMER
Omeros
1.9114 of 5 stars
$7.60
+10.0%
$31.40
+313.2%
-46.5%$475.32M$73.81M-3.82277
AKBA
Akebia Therapeutics
1.8581 of 5 stars
$2.71
+6.3%
$9.00
+232.1%
-10.9%$474.14M$295.31M-1.43380Gap Up
EVLO
Evelo Biosciences
1.9948 of 5 stars
$8.70
+3.6%
$21.92
+151.9%
+69.9%$465.10MN/A-3.642,018
GERN
Geron
1.7998 of 5 stars
$1.44
+8.3%
$5.50
+281.9%
-19.1%$463.61M$250K-4.3654
ACET
Adicet Bio
2.1665 of 5 stars
$14.49
+6.3%
$30.67
+111.6%
+11.1%$463.03M$17.90M-7.0382Analyst Report
News Coverage
Gap Down
High Trading Volume
BLU
BELLUS Health
2.3264 of 5 stars
$5.89
+8.3%
$12.00
+103.7%
+80.7%$461.41M$10K-7.1832Analyst Report
News Coverage
Gap Up
FLXN
Flexion Therapeutics
2.267 of 5 stars
$9.12
+0.0%
$12.43
+36.3%
N/A$458.93M$85.55M-4.54257News Coverage
SPRO
Spero Therapeutics
2.4414 of 5 stars
$14.17
+4.1%
$52.33
+269.3%
-19.6%$458.03M$9.33M-5.3189
VSTM
Verastem
2.0648 of 5 stars
$2.50
+4.8%
$6.33
+153.3%
+10.6%$455.47M$88.52M-5.6849Gap Up
ALBO
Albireo Pharma
2.0798 of 5 stars
$23.38
+3.3%
$79.80
+241.3%
-41.3%$450.74M$8.31M-9.0390
RIGL
Rigel Pharmaceuticals
1.9931 of 5 stars
$2.62
+5.7%
$9.50
+262.6%
-13.2%$448.04M$108.62M-29.11169
OLMA
Olema Pharmaceuticals
2.7 of 5 stars
$11.07
+5.1%
$60.67
+448.0%
-75.4%$445.99MN/A-6.2937Gap Up
High Trading Volume
MRSN
Mersana Therapeutics
1.7481 of 5 stars
$6.19
+1.9%
$25.25
+307.9%
-74.0%$445.14M$830K-2.89110
CALT
Calliditas Therapeutics AB (publ)
1.7581 of 5 stars
$17.00
+0.6%
$52.00
+205.9%
-50.0%$444.91M$90K-8.1046
GLSI
Greenwich LifeSciences
2.0333 of 5 stars
$33.93
+5.4%
$76.50
+125.5%
+529.5%$441.70MN/A0.002Analyst Report
News Coverage
Gap Up
AADI
Aadi Bioscience
1.5798 of 5 stars
$21.08
+2.7%
$43.75
+107.5%
+63.4%$440.45M$15M-1.5812
GRCL
Gracell Biotechnologies
1.4465 of 5 stars
$6.51
+0.6%
$34.50
+430.0%
N/A$439.42MN/A0.002,020Gap Up
This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.